



AURORA[®]

INVESTOR PRESENTATION

AUGUST 2019

Disclaimer


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this presentation include, but are not limited to, statements with respect to accretive earnings, statements with respect to the funded production capacity which may not be achieved or realized within the time frames stated or at all, the anticipated size and or revenue associated with the adult consumer market in Canada and the global market for medical marijuana. Forward looking statements are based on certain assumptions regarding Aurora, including expected growth, results of operations, performance, industry trends and growth opportunities. While Aurora considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Recipients are cautioned not to place undue reliance on forward-looking statements contained herein. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the early stage of the cannabis industry in Canada generally, realization of funded production estimates, income tax and regulatory matters; the ability of Aurora to implement its business strategies; competition; currency and interest rate fluctuations; the risk of difficulties in the integration of Aurora and MedReleaf, the estimated size of the adult consumer market for cannabis in Canada, the estimated size of the global medical cannabis market and other risks.

Recipients are cautioned that the foregoing risks are not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in Aurora’s public filings and the material change reports that will be filed in respect of this Transaction, which are, or will be, available on SEDAR.

Capturing Margin Throughout the Cannabis Value Chain

Aurora is a **leader** in the domestic consumer market as well as the domestic and international medical cannabis markets. To achieve large-scale growth and long-term, **sustainable profitability**, Aurora has identified a number of elements critical to driving the success of its strategy. This **dynamic growth strategy** will enable Aurora to capture greater margin across the entire **cannabis industry value chain**.



Aurora: leader in the global cannabis industry

Sector leader in **technology** across
operations and **product development**

Active in **5 continents** and **25 countries**

Medical cannabis industry leader in **Europe** and
Latin America

15 global production facilities⁽¹⁾ with
2 EU GMP certified⁽²⁾

18 strategic acquisitions across the
value chain since August 2016

40 Clinical Studies underway or
completed⁽³⁾ and over **77,000 medical
patients** served

1. Excludes facilities from the recently closed ICC Labs acquisition.
2. Includes 2 production facilities in Canada and 1 European distribution center
3. Studies include randomized clinical trials and observational studies in addition to several case studies.

Extensive Distribution Channels in Canada and Internationally




Industry Leading Scale

>625,000

kg/year funded capacity

15

Production facilities



1. Aurora defines production capacity as representing all planted rooms approved by Health Canada, factoring in anticipated harvests at maturity annualized for the following twelve (12) month period, based on an average historical yield per plant, as at February 15th 2019.

2. Excludes recently closed acquisition of ICC Labs.

3. Based on calendar year.

Cultivation Matters

Mass Scale, High-Quality and Low-Cost Production is Crucial for Success



Mass scale high-tech facilities designed to meet the fast-growing global demand for cannabis in the medical and adult usage markets

Focus on high-**quality products**, allows Aurora to service various end markets, starting with medical and pharma⁽¹⁾, through precise control of cultivation variables (nutrients, lighting, humidity, temperature, air flow, etc.)

Low-cost production enables Aurora to execute on its high-margin strategy


1. Medical cannabis requires consistent and high-quality product.

Strong Revenue, Patient and Production Growth



Significant Opportunity Across Medical, Consumer and Wellness Markets

Expected **global disruption** in the beverage, pharmaceutical, CPG and tobacco industries



Total global cannabis opportunity is **~\$200 billion**

Source: BMO Research and Deloitte

1. Estimated for Canadian Medical TAM assumes LPs obtain retail prices for cannabis.

2. Estimate for total potential market opportunity for Canadian Adult-Use.

3. Estimate consists of medical markets for the U.S., EU and LATAM markets only and assumes EU and LATAM TAM based on wholesale pricing while US TAM assumes retail pricing.

4. Estimate consists of adult-use markets for the U.S. and EU markets only and assumes that LPs obtain retail pricing for cannabis.

Significant Canadian Opportunities

Across Medical, Consumer, and Wellness Markets

Medical

Consumer

Product Mix



dry flower



oils



soft gels



gel caps



vape pens



edibles



infused
beverages

Margin (Outlook)

Improving as contribution from
derivatives increases

Enhanced Margin through Premium and
Innovative Products

Keys to Success

Patient capture
Drive down costs
Product **innovation**
Branding through **clinical trials**

R&D to develop high-margin products
Comprehensive **house of brands**
Leverage medical **reputation and credibility**

Successful Canadian Consumer Market Launch

17 awards

from the Canadian Cannabis Awards



Top 4 of 5

Best-Selling Products in B.C.⁽¹⁾



TANGERINE DREAM
San Rafael/71 MedReleaf



GREAT WHITE SHARK
San Rafael/71 MedReleaf



BLUE DREAM
Aurora by Aurora Cannabis



PINK KUSH
San Rafael/71 MedReleaf

Comprehensive portfolio of medical and consumer brands:



1. Sourced from BC Cannabis Stores website; data taken as of February 19th 2019 and represents the first two weeks of legal sales.

Significant Global Opportunities

Across Medical, Consumer, and Wellness Markets

Medical

Product Mix



dry flower



oils

Margin (Outlook)

Clinical Trials and New Treatment Uses
Drive Higher Margins

Keys to Success

Leveraging **early-mover advantage**
Higher-margin, pharma-grade **product innovation**
Strong medical brand and **market awareness**

Consumer



infused beverages



nutraceuticals



wellness products



recovery beverages

Innovative Product Formats and Brands to Extend Margins

Controlling distribution

First-mover into new countries to establish leading market share

Addressing the **non-prescription wellness market**

Poised to Capture the Global Hemp-CBD Opportunity

The global Hemp-CBD market is estimated to reach ~US\$22bn + by 2022⁽¹⁾

Growing Use Cases for CBD Products

Hemp-CBD is increasingly being used in a variety of products for a number of health & wellness purposes including: nutrition, inflammation reduction, boosting metabolism, lowering anxiety and improving overall mood



a leading processor & marketer of hemp based products and brands



Europe's largest producer, processor and supplier of organic hemp and hemp products



a European hemp processor and distributor



a global trailblazer in high-tech CBD extraction at a commercial scale



a South American pioneer in cannabis and hemp-based products

A Global Rational Market Builder

Leadership Across the Entire Value Chain



Over 30 years of experience in **designing** and engineering **high-tech, automated,** environmentally controlled greenhouses



Disruptive **extraction technology** to ensure low-cost, high-yield operations



Industry leading genetics research and **robust product innovation**, driven by the industry's largest science team



Robust domestic and **international distribution** networks spanning **98% of the Canadian population** and other locations worldwide



Well-recognized and respected medical and consumer brands with **strong consumer engagement** and customer care

Strategically Investing Across the Value Chain

Aurora is exceptionally **well-positioned**, through its diverse acquisitions and strategic initiatives completed to date, to capitalize on the **enormous opportunity** across the entire cannabis industry value chain in both domestic and international markets.

Acquisitions



Strategic Investments



Diverse Domestic Medical Distribution Networks

Medical Market

Aurora has agreements to collaborate with **PharmaChoice**, **Pharmasave** and Shoppers Drug Mart on the marketing, distribution, and sale of medical cannabis products through their respective networks of pharmacies, subject to Health Canada approval.

Consumer Market

Aurora's distribution network covers approximately 98 per cent of the Canadian population. The Aurora and **MedReleaf** brands, including **San Rafael '71** and **AltaVie**, have rapidly achieved a strong presence across the country, positioning Aurora well for rapid growth.



Establishing EU Market Leadership

European Union Population: **~465 million** | Market Opportunity: **~C\$98 billion**

GERMANY - The acquisition of Pedanios, now **Aurora Deutschland**, provides **distinct first-mover advantage** in the single largest federally legalized medical cannabis market with a population of **82+ million in Germany**

EU GMP certified facilities necessary for success in the EU markets

Aurora currently holds a **leading market share** in the German medical market

70+ employees across Germany and the EU

Germany has **broad insurance coverage** for medical cannabis, allowing for **substantially higher margins** and is expected to reduce margin compression over time

Selected by the German Federal Institute for Drugs and Medical Devices as one of three winners in the public tender to cultivate and distribute medical cannabis in Germany

DENMARK - First LP to ship medical cannabis to Denmark. Aurora also has Aurora Nordic, a 51% owned, 1,000,000 sq ft facility being built⁽¹⁾ in Odensk, along with a 100,000 sq ft retrofit facility

MALTA - First LP to receive cultivation LOI issued by the Maltese authorities to date and first LP to ship medical cannabis to Malta

UNITED KINGDOM - Authorities recently granted Aurora approval for its first shipment of medical cannabis into the UK from Canada

ITALY - Supplying cannabis to the Italian government through Aurora Europe. First LP to complete private export from Canada in April 2018

CZECH REPUBLIC - Supplying cannabis to Czech Medical Herbs s.r.o. ("CMH"), a Czech pharmaceutical wholesaler, for distribution to pharmacies throughout the country

LUXEMBOURG - Selected by the Luxembourg Health Ministry as the exclusive supplier in a public bid to supply a second delivery of medical cannabis

POLAND - First LP to receive cannabis import permit from the Polish Ministry of Health

PORTUGAL - Joint venture partnership with Gaia Pharm Lda. to develop facility and produce medical cannabis and derivative products

Leadership in Latin America

Population: ~650 million

ICC Labs

Estimated funded production capacity over 450,000 kg per annum of bulk hemp and cannabis

Two facilities currently under development adding 124,000 sq ft of greenhouse production in Colombia and a 1,000,000 sq ft facility in Uruguay

Outdoor grow sites, with a potential total area of over 800 acres

Broad portfolio of dried flower and higher margin products, including tablets, softcaps, ointments, creams, drops infused syrups, and patches

South America's first GMP-compliant, cannabis science laboratory, to be scaled up to 150,000 kg extraction capacity per year



Significant Latin American Market Opportunity with Clear Demand for Legal Regulated Cannabis Products

Uruguay was the first country in the world to fully legalize medical and adult use cannabis, allowing cultivation of CBD rich bulk hemp with THC concentrations of up to 1%

Colombia legalized medical cannabis in 2015 and MED Colombia received its cultivation license for THC cannabis and its derivatives in 2017

Through the acquisition of Farmacias Magistrales, Aurora will become Mexico's first and only federally licensed importer of medical cannabis containing over 1% THC

Q3 2019 Results

\$ in Canadian millions, unless otherwise noted	Q3 2019	Q2 2019	Change (%)	Q3 2018	Change (%)
Financial					
Net Revenue	\$65.1	\$54.1	20%	\$16.1	305%
Gross Margin on Net Cannabis Revenue ⁽¹⁾	55%	54%	1%	59%	(4%)
Biological Inventory	\$118.0	\$79.9	48%	\$28.4	314%
Cash Cost to Produce (per gram of dried cannabis sold) ⁽²⁾	\$1.42	1.92	(26%)	\$1.53	(7%)
Operational					
Average Net Selling Price of Dried Cannabis	\$5.86	\$6.23	(6%)	\$7.30	(20%)
Average Net Selling Price of Cannabis Extracts	\$11.01	\$10.00	10%	12.83	(14%)
Kilograms Produced	15,590	7,822	99%	1,206	1,193%
Kilograms Sold	9,160	6,999	31%	1,353	577%

1. Represents the gross margin on net cannabis revenue before fair value adjustments. Excludes revenues from patient counselling services, design, engineering, and construction services, and analytical testing services. Gross margin on net cannabis revenue is a non-IFRS financial measure. See "Gross Margin" section of Q2 2019 MD&A for reconciliation to IFRS figure.

2. Represents the cash cost of sales per gram of dried cannabis produced and sold by consolidated Aurora, excluding costs to sell such as packaging costs. Cash cost of sales per gram produced is a non-IFRS financial measure. See "Cash Cost of Sales of Dried Cannabis and Cash Cost to Produce Dried Cannabis Sold – Aurora Produced Cannabis" section of Q2 2019 MD&A for reconciliation to IFRS figure.

Aurora's Path to Profitability



NEAR TERM

- Drive down costs by leveraging massive scale
- Protecting against eventual margin compression
- **Leadership** in Global Medical Markets
- Invest heavily in R&D to **create optionality**
- Brand building and protection through high-quality product

MEDIUM TERM

- Harvest Canadian market cash flow from **near-term domestic** strategy
- Leverage R&D work in **higher-margin** products (Vapes, CBD infusions, etc.)
- Global Medical leading to higher-margin sales

LONG TERM

- Branded **high-margin products** across both global medical and consumer markets
- **R&D supports** product development, brand development, and continued improvement in yields

High-Margin Strategy

A Sustainable Long-term Business Model

Maximizing average selling price through:

Leadership in key international markets allowing strategic focus on highest margin options (medical, new products)

Full margin capture in international markets through direct ownership of distribution channels

Commitment to science and product development > developing new higher margin products and marketable IP

Driving down overall production per gram cash costs through:

Commitment to science and technology > increasing yields through genetics, low per gram operating costs from world-class automation and replicable large-scale pharma-style production

Low-input cost locations

Leveraging massive scale to spread costs over a large volume of product

Production costs at scale are projected to be well **below \$1 per gram**



Scientific Leadership Advantage

Industry Leading Science & Innovation Team to Drive Medical Advancements



Jon Page, PhD
Chief Science Officer

First scientist to sequence the cannabis genome and provide deep insights into the biosynthesis of cannabinoids



Jason Dyck, PhD
Human Scientist, Director

Professor in the Department of Pediatrics at the University of Alberta and a Canada Research Chair in Molecular Medicine



Kelly Narine, PhD
Head of Biomedical Research

PhD in Medical Genetics from the University of Alberta; Deep expertise in translating research into positive health outcomes



Shane Morris, PhD
Head of Product Development

Experienced executive in the cannabis industry since 2015; previously part of the senior leadership team at Hydropharmacy

40 Clinical Studies Underway or Completed⁽¹⁾

7 Pre-Clinical Studies in Progress

27 Clinical Studies Currently Under Discussion

With Strong IP Retention on Clinical Studies

Clinical Research Areas include: Pain, Epilepsy, PTSD, Anxiety, Opioid Sparing, Cancer, Neurodegeneration

Partnering with Leading Institutions and Universities



1. Studies include randomized clinical trials and observational studies in addition to several case studies.

Proven Management Team Driving High Pace of Execution



Terry Booth

Chief Executive Officer

CEO of 6 successful companies with 25 years experience in highly regulated industries



Steve Dobler

President

Successful entrepreneur, member of many public companies' board of directors. Responsible for raising substantial funds for Aurora



Glen Ibbott

Chief Financial Officer

Strong senior financial executive with extensive life sciences sector experience



Cam Battley

Chief Corporate Officer

Deep experience in pharma and cannabis sectors, Board member Cannabis Canada



Neil Belot

Chief Global Business Development Officer

Former executive director of Cannabis Canada - Canada's trade association for Licensed Producers



Jillian Swainson

Chief Legal Officer

Former Partner at Brownlee LLP with experience in corporate, commercial, intellectual property and securities law and providing advisory services in highly regulated industries



Darren Karasiuk

Chief Commercial Officer

Successfully launched Aurora into the Canadian consumer market, achieving strong brand recognition for Aurora's brands. Former VP Insights & Advisory at Deloitte



Carey Squires

EVP, Corporate Development & Strategy

Former Managing Director and Co-Head of Equity-Linked Capital Markets for BMO Capital Markets, with deep experience in the U.S. and Canadian capital markets,



Debra Wilson

Chief Human Resources Officer

Seasoned leader with more than 25 years' experience in human resources, developing and practicing leading-edge methods



Darryl Vleeming

Chief Information Officer

Over 20 years of experience in Senior IT leadership, project delivery, and IT strategic planning at publicly traded international corporations.



Jonathan Page

Chief Science Officer

Globally renowned cannabis scientist. Co-lead of the Canadian team of scientists who first sequenced the cannabis genome. Co-founder of Anandia Labs



Allan Cleiren

Chief Operating Officer

Experienced operational executive with nearly three decades leadership experience at private and public companies

Strong Board of Directors



Michael Singer

Executive Chairman

Former CFO, Clementia Pharmaceuticals
Former CFO, Bedrocan Canada Corp.



Terry Booth

Chief Executive Officer

CEO of 6 successful companies
25 years experience in highly-regulated industries



Steve Dobler

President

Successful entrepreneur, member of many public companies' board of directors. Responsible for raising substantial funds for Aurora



Shan Atkins

Director

Certified Public Accountant with over 20 years of corporate leadership experience. Served on public company boards, including Shoppers Drug Mart



Dr. Jason Dyck

Director

Professor in the Department of Pediatrics and Director of Cardiovascular Research Centre, University of Alberta



Norma Beauchamp

Director

Retired President and CEO of Cystic Fibrosis Canada, Director of Acerus Pharmaceuticals



Ronald Funk

Director

Deep consulting business experience, former VP Corporate Affairs and Competitive Improvement for Rothmans



Adam Szweras

Director

Experienced securities lawyer, Founder of US developer of marijuana, hemp oil, and edible products

Deep Expertise and Background in Cannabis, Hemp, Tobacco and Pharmaceutical

Checking All the Boxes - A Platform for Accelerated Growth



**Industry-Leading
Scale**




**Low Production Costs
and Industry-Leading
Yields**



**Extensive Distribution
Channels in Canada
and Internationally**



**Proficient M&A
Capabilities**



**Proven Execution &
Agility Across Value
Chain**



**Enhanced
Diversification**



**Award-Winning Product
Lines Support Brand
Leadership**



**Innovation and R&D
Excellence**



**Business Integration
Expertise**



**Enhanced Capital
Markets Profile**



AUROLA[®]

CONTACT INFORMATION

Cam Battley

Chief Corporate Officer
cam@auroramj.com

Ananth Krishnan

VP, Capital Markets & Investor
Relations
ananth.krishnan@auroramj.com

Rob Kelly

Director, Investor Relations
rob.kelly@auroramj.com

Investor Relations

1-855-279-4652
ir@auroramj.com



AURORA[®]

APPENDIX

Industry-Leading Scale

15 Production Facilities – Expected to Have Over 625,000 kg/year in Capacity by Mid-2020

	LOCATION	SIZE	CAPACITY	STATUS	CULTIVATION	LICENSE SALE	EU GMP
Aurora Mountain	Mountain View, Alberta, Canada	55,200 sq.ft.	4,800 kg/year	Operating since 2015	●	●	●
Aurora Vie	Pointe Claire, Quebec, Canada	40,000 sq.ft.	4,000 kg/year	Operating since June 2018	●	●	
Aurora Eau	Lachute, Quebec, Canada	48,000 sq.ft.	4,500 kg/year	Facility in full operation	●	●	
Aurora Sky	Edmonton, Alberta, Canada	800,000 sq.ft.	>100,000 kg/year	Facility in full operation	●	●	
Aurora Sun	Medicine Hat, Alberta, Canada	1,620,000 sq.ft.	>230,000 kg/year	Full construction to be completed by mid calendar 2020			
Aurora Nordic 1	Odense, Denmark	100,000 sq.ft.	8,000 kg/year	Facility construction complete	●		
Aurora Nordic 2	Odense, Denmark	1,000,000 sq.ft.	>120,000 kg/year	Full construction to be complete by mid calendar 2020			
Aurora Prairie	Saskatoon, Saskatchewan, Canada	97,000 sq.ft.	19,000 kg/year	Operating since 2004. Facility upgrades underway	●	●	
Aurora Ridge	Markham, Ontario, Canada	55,000 sq.ft.	7,000 kg/year	Operating since 2014	●	●	●
Aurora River	Bradford, Ontario, Canada	210,000 sq.ft.	28,000 kg/year	Facility in full operation	●	●	
Exeter	Exeter, Ontario, Canada	1,000,000 sq.ft.	105,000 kg/year	Land and building purchased			
Whistler Alpha Lake	Whistler, British Columbia, Canada	12,500 sq. ft.	500 kg/year	Operating since 2014	●	●	
Whistler Pemberton	Pemberton, British Columbia, Canada	62,000 sq. ft.	>5,000 kg/year	Phase 1 in operation. Phase 2 expected to be completed in September 2019	●		
ICC Labs	Canelones, Uruguay	21,000 sq.ft.	27,135 kg/year	Facility in full operation	●	●	
Aurora Portugal	Portugal	38,000 sq.ft.	4,000 kg/year	Phase 1 expected to be completed in calendar Q3 2020			

Executing on the Global Cannabis Opportunity

Distribution



- Largest Canadian private retailer of adult beverages including beer, wine, spirits
- Bringing a state-of-the-art consumer retail concept featuring a variety of brands and wide selection of cannabis products
- Opening 37 stores and retrofitting existing liquor stores into cannabis retail outlets
- Investment aids rapid development of Canadian cannabis retail network

Extraction



- ~17% ownership interest
- Proprietary technology provides superior ingredient purity, yield, and cost
- Aligned with strategy of becoming the leading vertically integrated player considering the growing importance of cannabis extracts

Cultivation



- Existing investment accomplished objective of securing supply agreement for 20% of TGO's organic cannabis production
- First mover in Australia focused on developing medicinal cannabis products

Plant Science and Product R&D



- Leading processor & marketer of hemp-based products and brands



- Developer of advanced grow light technologies



- Leading organic waste technology company that developed an on-site system that turns organic waste into clean water



- Provides safe, flexible, simple and innovative drug delivery systems for pain management therapies and treatments



- Platform specializing in softgel encapsulation; expands Aurora's differentiated, higher-margin product offerings

Consumer Engagement and Brands



- Curated cannabis retailer with access to "craft" cannabis supply, and diverse brands for consumers



- Comprised of a portfolio of conscious lifestyle brands



- Technology enables the production of over 75 different pre-rolled product types, addressing a wide variety of market demands



- Developing a network of cannabis and accessory retail stores, as well as manufacturing and distributing branded cannabis accessories

Select Portfolio of Clinical Studies

Indication	Research Partners	Trial Name	Phase
Cancer Pain Management	OCOG, Sunnybrook Health Science Center, Hamilton Health Sciences, Juravinski Cancer Center	Cannabis Oil for Pain Effectiveness	II
Osteoarthritis	McGill University Health Network & Queen Elizabeth II Health Science Center	Vaporized Cannabis for Painful Osteoarthritis of the Knee	Ila
Epilepsy	Royal University Hospital and University of Saskatchewan	CBD in Children with Refractory Epilepsy	II
Tourette's Syndrome	University Health Network	Vaporized Cannabis in Adults with Tourette's Syndrome	II
Pharmacokinetics	N.A.	Comparative Bioavailability and Pharmacogenomics Study of THC on Healthy Volunteers	I
Epilepsy	Ontario Brain Institute, UofT, University Health Network, University Hospital London, Toronto Western Hospital	CBD and THC Given as Adjunctive Therapy to Adults with Refractory Seizures	III
Genetics	Mount Sinai Hospital	Identification of Genetic Biomarker Signatures associated with Cannabis Efficacy and Dose in Survey Patients	N.A.
Chronic Pain	CFL Alumni Association, CannaConnect Clinic	Assessing the Effects of Medical Cannabis on Pain and Related Quality of Life in Retired Athletes with Chronic Pain	N.A.
Multiple Medical Conditions	University of Alberta	Health and Economics-Based Outcomes of Cannabis-Based Therapies	N.A.